Stock Watch: Ulterior Motives For Talking Down Pfizer
Why Do Analysts Underplay Pfizer’s Third-Quarter Results?
Pfizer’s pandemic-related windfalls might be prompting some investors and analysts to try steering the resulting largesse towards their own favored acquisition candidates.
